Chicoric acid analogues as HIV-1 integrase inhibitors

Journal of Medicinal Chemistry

Volumn 42, Issue 8, 1999, Pages 1401-1414

  Lin, Zhaiwei ^a   Neamati, Nouri ^a   Zhao, He ^a   Kiryu, Yoshimitsu ^a   Turpin, Jim A ^c,e   Aberham, Claudia ^b   Strebel, Klaus ^b   Kohn, Kurt ^a   Witvrouw, Myriam ^d   Pannecouque, Christophe ^d   Debyser, Zeger ^d   De Clercq, Erik ^d   Rice, William G ^c,f   Pommier, Yves ^a   Burke Jr , Terrence R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c SAIC FREDERICK INC   (United States)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^e SOUTHERN RESEARCH INSTITUTE   (United States)

^f Achillion Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CICHORIC ACID; ESTER; INTEGRASE INHIBITOR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; VIRUS INFECTION; VIRUS INHIBITION;

ANIMALS; ANTI-HIV AGENTS; CAFFEIC ACIDS; CELL LINE; DRUG EVALUATION, PRECLINICAL; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HIV-2; HUMANS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; SUCCINATES; VIRUS REPLICATION;

EID: 0033594376     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980531m     Document Type: Article

References (44)

1. LaFemina, R. L.; Schneider, C. L.; Robbins, H. L.; Callahan, P. L.; LeGrow, K.; Roth, E.; Schleif, W. A.; Emini, E. A. Requirement of active human immunodeficiency virus type 1 integrase for productive infection of human T-lymphoid cells. J. Virol. 1992, 66, 7414-7419.
2. Sakai, H.; Kawamura, M.; Sakuragi, J.; Sakuragi, S.; Shibata, R.; Ishimoto, A.; Ono, H.; Ueda, S.; Adachi, A. Integration is essential for efficient gene expression of human immunodeficiency virus type 1. J. Virol. 1993, 7, 1169-1174.
3. Taddeo, B.; Haseltine, W. A.; Farnet, C. M. Integrase mutants of human immunodeficiency virus type 1 with a specific defect in integration. J. Virol. 1994, 68, 8401-8405.
4. Engelman, A.; Englund, G.; Orenstein, J. M.; Martin, M. A.; Craigie, R. Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J. Virol. 1995, 69, 2729-2736.
5. Clercq, E. D. Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections. J. Med. Chem. 1995, 38, 2491-2517.
6. Pommier, Y.; Pilon, A. A.; Bajaj, K.; Mazumder, A.; Neamati, N. Review Article: HIV-1 integrase as a target for antiviral drugs. Antiviral Chem. Chemother. 1997, 8, 463-483.
7. Katz, R. A.; Merkel, G.; Kulkosky, J.; Leis, J.; Skalka, A. M. The avian retroviral IN protein is both necessary and sufficient for integrative recombination in vitro. Cell 1990, 63, 87-95.
8. Craigie, R.; Mizuuchi, K.; Bushman, F. D.; Engleman, S. A. A rapid in vitro assay for HIV DNA integration. Nucleic Acid Res. 1991, 19, 2729-2734.
9. Neamati, N.; Sunder, S.; Pommier, Y. Design and discovery of HIV-1 integrase inhibitors, Drug. Discov. Today 1997, 2, 487-498.
10. Fesen, M. R.; Pommier, Y.; Leteurtre, F.; Hiroguchi, S.; Yung, J.; Kohn, K. Inhibition of HIV-1 integrase by flavones, caffeic acid phenethlyl ester (CAPE) and related compounds. Biochem. Pharmacol. 1994, 48, 595-608.
11. Kim, H. J.; Woo, E. R.; Shin, C. G.; Park, H. A new flavonol glycoside gallate ester from Acer okamotoanum and its inhibitory activity against human immunodeficiency virus-1 (HIV-1) integrase. J. Nat. Prod. 1998, 61, 145-148.
12. Eckart, E.; Pertz, H.; Kaloga, M.; Schulz, J.; Fesen, M. R.; Mazumder, A.; Pommier, Y. (-)-Arctigenin as a lead structure for inhibitors of human immunodeficiency virus type-1 integrase. J. Med. Chem. 1996, 39, 86-95.
13. Mazumder, A.; Gazit, A.; Levitzki, A.; Nicklaus, M.; Yung, J.; Kohlhagen, G.; Pommier, Y. Effects of tyrphostins, protein kinase inhibitors, on human immunodeficiency virus type 1 integrase. Biochemistry 1995, 34, 15111-15122.
14. LaFemina, R. L.; Graham, P. L.; LeGrow, K.; Hastings, J. C.; Wolfe, A.; Young, S. D.; Emini, E. A.; Hazuda, D. Inhibition of human immunodeficiency virus integrase by bis-catechols. Antimicrob. Agents Chemother. 1995, 39, 320-324.
15. Burke, T. R.; Fesen, M. R.; Mazumder, A.; Wang, J.; Carothers, A. M.; Grunberger, D.; Driscoll, J.; Kohn, K.; Pommier, Y. Hydroxylated aromatic inhibitors of HIV-1 integrase. J. Med. Chem. 1995, 38, 4171-4178.
16. Zhao, H.; Neamati, N.; Mazumder, A.; Sunder, S.; Pommier, Y.; Burke, T. R., Jr. Arylamide inhibitors of HIV-1 integrase. J. Med. Chem. 1997, 40, 1186-1194.
17. Stanwell, C.; Ye, B.; Yuspa, S. H.; Burke, T. R., Jr. Cell protein cross-linking by erbstatin and related compounds. Biochem. Pharmacol. 1996, 52, 475-480.
18. Mahmood, N.; Moore, P. S.; De Tommasi, N.; De Simone, F.; Hay, A. J.; Pizza, C. Inhibition of HIV infection by caffeolyquinic acid derivatives. Antiviral Chem. Chemother. 1993, 4, 235-240.
19. Robinson, W. E.; Reinecke, M. G.; AbdelMalek, S.; Jia, Q.; Chow, S. A. Inhibitors of HIV-1 replication that inhibit HIV integrase. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 6326-6331.
20. Neamati, N.; Hong, H. X.; Sunder, S.; Milne, G. W. A.; Pommier, Y. Potent inhibitors of human immunodeficiency virus type 1 integrase: Identification of a novel four-point pharmacophore and tetracyclines as novel inhibitors. Mol. Pharmacol. 1997, 52, 1041-1055.
21. Neamati, N.; Hong, H. X.; Mazumder, A.; Wang, S. M.; Sunder, S.; Nicklaus, M. C.; Milne, G. W. A.; Proksa, B.; Pommier, Y. Depsides and depsidones as inhibitors of HIV-1 integrase: Discovery of novel inhibitors through 3D database searching. J. Med. Chem. 1997, 40, 942-951.
22. McDougall, B.; King, P. J.; Wu, B. W.; Hostomsky, Z.; Reinecke, M. G.; Robinson, W. E. Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. Antimicrob. Agents Chemother. 1998, 42, 140-146.
23. Robinson, W. E.; Cordeiro, M.; AbdelMalek, S.; Jia, Q.; Chow, S. A.; Reinecke, M. G.; Mitchell, W. M. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: Inhibition of the core catalytic domain of human immunodeficiency virus integrase. Mol. Pharmocol. 1996, 50, 846-855.
24. King, P. J.; Robinson, W. E., Jr. Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single point mutation at amino acid 140 of integrase. J. Virol. 1998, 72, 8420-8424.
25. Zhao, H.; Burke, T. R., Jr. Facile syntheses of (2R,3R)-(-)-and (2S,3S)-(+)-chicoric acids. Synth. Commun. 1998, 28, 737-740.
26. Mazumder, A.; Neamati, N.; Sunder, S.; Schulz, J.; Pertz, H.; Eich, E.; Pommier, Y. Curcumin analogues with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action. J. Med. Chem. 1997, 40, 3057-3063.
27. Weislow, O. W.; Kiser, R.; Fine, D.; Bader, J.; Shoemaker, R. H.; Boyd, M. R. New soluble-formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS antiviral activity. J. Natl. Cancer Inst. 1989, 81, 577-586.
28. Kimpton, J.; Emerman, M. Detection of replication competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated β-galactosidase gene. J. Virol. 1992, 66, 2232-2239.
29. Rice, W. G.; Supko, J. G.; Malspeis, L.; Buckheit, R. W., Jr.; Clanton, D. J.; Bu, M.; Graham, L.; Schaeffer, C. A.; Turpin, J. A.; Domagala, J.; Gogliotti, R.; Bader, J. P.; Halliday, S. M.; Coren, L.; Sowder, R. C., II; Arthur, L. O.; Henderson, L. E. Inhibitors of HIV nucleocapsid protein zinc fingers as candidates for the treatment of AIDS. Science 1996, 270, 1194-1197.
30. Mazumder, A.; Neamati, N.; Sunder, S.; Owen, J.; Pommier, Y., Eds.; Humana Press: Totowa, NJ, 1997, in press.
31. Clanton, D. J.; Buckheit, R. W., Jr.; Terpening, S. J.; Kiser, R.; Mongelli, N.; Borgia, A. L.; Schultz, R.; Narayanan, V.; Bader, J. P.; Rice, W. G. Novel sulfonated and phosphonated analogues of distamycin which inhibit the replication of HIV. Antiviral Res. 1995, 27, 335-354.
32. Bader, J. P.; McMahon, J. B.; Schultz, R. J.; Narayanan, V. L.; Pierce, J. B.; Harrison, W. A.; Weislow, O. S.; Midelfort, C. F.; Boyd, M. R. Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 6740-6744.
33. Kageyama, S.; Mimoto, T.; Murakawa, Y.; Nomizu, M.; Ford, H., Jr.; Shirasaka, T.; Gulnik, S.; Erickson, J.; Takada, K.; Hayashi, H.; Broder, S.; Kiso, Y.; Mitsuya, H. In vitro antihuman immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine. Antimicrob. Agents Chemother. 1993, 37, 810-817.
34. Buckheit, R. W., Jr.; Roberson, J. L.; Lackman-Smith, C.; Wyatt, J. R.; Ecker, D. J. Potent and specific inhibition of HIV envelope-mediated cell fusion and virus binding by G quartet-forming oligonucleotide (ISIS 5320). AIDS Res. Hum. Retroviruses 1994, 10, 1497-1506.
35. Rice, W. G.; Schaeffer, C. A.; Graham, L.; Bu, M.; McDougal, J. S.; Orloff, S. L.; Villinger, F.; Young, M.; Oroszlan, S.; Fesen, M. R.; Pommier, Y.; Mendeleyev, J.; Kun, E. The site of action of 3-nitrosobenzamide on the infectivity process of human immunodeficiency virus in lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 9721-9724.
36. Miyoshi, I.; Tagushi, H.; Kobonishi, I.; Yoshimoto, S.; Ohtsuki, Y.; Shiraishi, Y.; Agai, T. Type C virus-producing cell lines from adult T cell leukemia. Gann. Monogr. 1982, 28, 219-228.
37. Popovic, M.; Sarngadharan, M. G.; Read, E.; Gallo, R. C. Detection and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984, 224, 497-500.
38. Barre-Sinoussi, F.; Chermann, J. C.; Rey, F.; Nugeyre, M. T.; Chamaret, S.; Gruest, J.; Dauguet, C.; Axler-Blin, C.; Vezinet-Brun, F.; Rouzioux, C.; Rozenbaum, W.; Montagnier, L. Isolation of a T-lymphotropic retrovirus from a patient at risk of AIDS. Science 1983, 220, 868-871.
39. Pauwels, R.; Balzarini, J.; Baba, M.; Snoeck, R.; Schols, D.; Herdewijn, P.; Desmyter, J.; Clercq, E. D. Rapic and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 1988, 20, 309-321.
40. Turpin, J. A.; Terpening, S. J.; Schaeffer, C. A.; Yu, G.; Glover, C. J.; Felsted, R. L.; Sausville, E. A. Inhibitors of human immunodeficiency virus type 1 zinc fingers prevent normal processing of Gag precursors and result in the release of noninfectious virus particles. J. Virol. 1996, 70, 6180-6189.
41. Rice, W. G.; Baker, D.; Schaeffer, C. A.; Graham, L.; Bu, M.; Terpening, S.; Clanton, D.; Schultz, R.; Bader, J. P.; Buckheit, R. W., Jr.; Field, L.; Turpin, J. A. Inhibition of multiple phases of HIV-1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins. Antimicrob. Agents Chemother. 1997, 41, 419-426.
42. Bushman, F. D.; Craigie, R. Activities of human immunodeficiency virus (HIV) integration protein in vitro; specific cleavage and integration of HIV DNA. Proc. Natl. Acad. Sci. U.S.A. 1991, 58, 1339-1343.
43. Adachi, A.; Gendelman, H. E.; Koening, S.; Folks, T.; Willey, R.; Rabson, A.; Martin, M. A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 1986, 59, 284-291.
44. Willey, R. L.; Smith, D. H.; Lasky, L. A.; Theodore, T. S.; Earl, P. L.; Moss, B.; Capon, D. J.; Martin, M. A. In vitro mutagenesis identifies a region within the envelope gene of the human immunodeficiency virus that is critical for infectivity. J. Virol. 1988, 62, 139-147.